Prednisone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Prednisone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Prednisone is a synthetic glucocorticoid long used as a systemic anti-inflammatory and immunosuppressive agent across autoimmune, inflammatory, and oncologic conditions. The TxGNN model predicts it may be effective for Alopecia Areata, with 33 clinical trials and 20 publications retrieved in this evidence pack, though only a small subset directly test prednisone in this indication. Evidence is largely observational/case-series in nature rather than confirmatory randomized trial data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no New Zealand market authorization on file); prednisone is generally used as a broad-spectrum systemic corticosteroid for anti-inflammatory and immunosuppressive therapy |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not directly available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, prednisone is a synthetic glucocorticoid with broad anti-inflammatory and immunosuppressive activity — it is used both as monotherapy for autoimmune/inflammatory disease and as an adjunct in combination chemotherapy regimens (e.g., R-CVP, BEACOPP, docetaxel-prednisone), as reflected in several of the retrieved clinical trials below.
Alopecia areata (AA) is a T-cell mediated autoimmune hair-loss disorder in which inflammatory lymphocytic infiltration attacks the hair follicle. Prednisone's broad immunosuppressive/anti-inflammatory mechanism maps directly onto this pathology by suppressing the peri-follicular T-cell attack. Clinically, systemic corticosteroids — alone or combined with methotrexate — have long been used off-label for severe or rapidly progressive AA, which lends this mechanistic link reasonable plausibility even though rigorous prednisone-monotherapy RCT data is limited.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02037191 | Phase 3 | Completed | 90 | RCT of methotrexate vs. placebo in severe alopecia areata, with secondary treatment arm combining methotrexate + low-dose prednisone — the most directly relevant trial, though prednisone effect is not isolated from methotrexate (Grade B) |
| NCT03021499 | Phase 3 | Completed | 358 | Voclosporin (a calcineurin inhibitor, not prednisone) vs. placebo in active lupus nephritis; provides autoimmune-disease context only (Grade C) |
| NCT01652261 | Phase 3 | Withdrawn | 0 | BEACOPP regimen (includes prednisone) vs. ABVD in advanced Hodgkin lymphoma; linked to AA only via reported AA–Hodgkin comorbidity in the literature (Grade C) |
| NCT01283139 | Phase 2 | Completed | 834 | Sifalimumab vs. placebo in systemic lupus erythematosus; neither AA- nor prednisone-specific (Grade C) |
Note: The keyword search also matched ~29 additional trials (mostly systemic lupus erythematosus, prostate cancer, and lymphoma studies) where "prednisone" appeared incidentally as a background/combination therapy rather than as the studied intervention for alopecia areata. These were excluded above as low-relevance.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36884234 | 2023 | RCT | JAMA Dermatology | 2-step double-blind RCT: methotrexate alone vs. methotrexate + low-dose prednisone in alopecia totalis/universalis |
| 1444509 | 1992 | Review | Archives of Dermatology | Review of AA therapies including corticosteroids — efficacy, safety, and mechanism |
| 4571041 | 1973 | Cohort | Archives of Dermatology | Immunologic studies of AA and treatment outcomes with prednisone |
| 26735937 | 2016 | Cohort | Dermatology (Basel) | Methotrexate combined with low-to-moderate dose corticosteroids for severe AA |
| 791152 | 1976 | Case series/Follow-up | Archives of Dermatology | 18 patients on alternate-day prednisone for AA; initial response but limited long-term benefit and notable steroid side effects |
| 20804894 | 2010 | Case series | Annales de Dermatologie et de Vénéréologie | Efficacy and safety of once-monthly oral pulsed prednisone in AA |
| 9732014 | 1998 | Case series | International Journal of Dermatology | Severe AA treated with systemic corticosteroids, demonstrated as effective |
| 37467740 | 2023 | Case series | Clinical and Experimental Dermatology | Baricitinib + low-dose corticosteroids for very severe AA (8-case series) |
| 41958306 | 2026 | Case series | J Eur Acad Dermatol Venereol | Baricitinib + low-dose prednisone for very severe AA, retrospective series |
| 13368875 | 1956 | Case series | Medical Times | Early report on AA/partialis/totalis treated with cortisone, hydrocortisone, prednisone, and prednisolone |
New Zealand Market Information
Prednisone currently has no market authorizations on file in New Zealand under this evidence pack (0 licenses; market status: not marketed). No product/dosage-form data is available to populate a licenses table.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data were not available in this evidence pack — TFDA/Medsafe package insert retrieval is flagged as a Blocking data gap.)
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale for prednisone in alopecia areata is plausible and consistent with existing off-label clinical practice, but direct supporting evidence is limited to observational cohorts, case series, and one RCT where prednisone was an adjunct to methotrexate rather than the primary studied intervention (Evidence Level L3). Combined with the absence of NZ market presence and a Blocking safety data gap that prevents even an initial safety screen (S1), the evidence does not yet support proceeding.
To proceed, the following is needed:
- TFDA/Medsafe package insert (warnings, contraindications) — currently a Blocking gap
- Formal mechanism of action documentation from DrugBank or equivalent source
- Drug-drug interaction (DDI) data, currently returning "not found"
- A dedicated trial or subgroup analysis isolating prednisone's effect from methotrexate combination therapy in AA
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.